Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate

Sitagliptin reduces the ACR through decreasing both blood pressure and the eGFR, with no correlation with a decrease in HbA1c over a three-month period. These results may reflect the direct action of sitagliptin on the kidneys (Journal of Diabetes)